尼莫地平联合辛伐他汀防治自发性蛛网膜下腔出血后脑血管痉挛

Clinical Effecacy of Nimodipine Combined with Simvastatin on Cerebral Vasospasm Following Subarachnoid Hemorrhage

目的:探讨尼莫地平联合辛伐他汀防治自发性蛛网膜下腔出血(SAH)后血管痉挛(CVS)的临床疗效及安全性。方法:83例SAH患者随机分为对照组41例和观察组42例。2组患者在给予SAH常规治疗的基础上,对照组给予尼莫地平治疗,观察组给予尼莫地平联合辛伐他汀治疗,疗程均为4周。比较2组疗效、CVS及其他不良事件的发生率。结果:治疗后,观察组患者的痊愈率(45.2%)明显高于对照组(24.4%),CVS的发生率(9.5%)低于对照组(26.8%),不良事件发生率(9.5%)低于对照组(39.0%),Hunt-Hess分级为I级、II级的患者数量明显多于对照组(均P<0.05)。结论:尼莫地平联合辛伐他汀治疗有助于降低SAH后CVS的发生率,降低不良反应,提高疗效。

Objective： To observe the clinical efficacy and safety of Nimodipine combined with Simvastatin in the treatment of cerebral vasospasm （CVS） after subarachnoid hemorrhage （SAH）. Methods： Eight-three SAH patients were randomly divided into groups control （n=41） and observation （n=42）. The two groups were given conventional treatment for SAH and Nimodipine for 4 weeks, and the observation group was given Simvastatin additionally. The efficacy, incidence rate of CVS and other adverse events in the 2 groups were compared. Re- suits： The recovery rate of the observation group （45.2%） was significantly higher than that in the control group （24.4%） （P〈0.05）. The incidence of CVS in the observation group（26.8%） was lower than that in the control group （9.5%） （P〈0.05）, and the incidence of adverse events （9.5%） was lower than that of the control group （39.0%） （P〈0.05）. In the observation group, the number of patients in grades I and II were more than in the con- trol group （P〈0.05）. Conclusion： Nimodipine combined with Simvastatin can reduce the incidence of CVS and adverse reaction following SAIl, and improve the curative effect.